Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

REPLIGEN CORP Director's Dealing 2022

Nov 14, 2022

30826_dirs_2022-11-14_22ab7bd8-65fa-4674-b836-07756bd06b94.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REPLIGEN CORP (RGEN)
CIK: 0000730272
Period of Report: 2022-11-11

Reporting Person: Hunt Anthony (Director, Chief Executive Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-11-11 Common Stock M 25000 $33.87 Acquired 203265 Direct
2022-11-11 Common Stock S 25000 $200.00 Disposed 178265 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-11-11 Stock Option (Right to Buy) $33.87 M 25000 Acquired 2028-02-29 Common Stock (25000) Direct

Footnotes

F1: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 14, 2021.

F2: This option is fully vested and exercisable.